(3R,5S)-5-{[4-({3-chloro-4-[(5-methyl-3-isoxazolyl) oxy] phenyl} amino) thieno[3,2-d]pyrimidin-6-yl] ethynyl}-3-pyrrolidinyl 4-morpholinecarboxylate | 833479-08-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: (3R,5S)-5-{[4-({3-chloro-4-[(5-methyl-3-isoxazolyl) oxy] phenyl} amino) thieno[3,2-d]pyrimidin-6-yl] ethynyl}-3-pyrrolidinyl 4-morpholinecarboxylate
• 英文别名: (3R,5S)-5-{2-[4-({3-chloro-4-[(5-methyl-1,2-oxazol-3-yl)oxy]phenyl}amino)thieno[3,2-d]pyrimidin-6-yl]ethynyl}pyrrolidin-3-yl morpholine-4-carboxylate；[(3R,5S)-5-[2-[4-[3-chloro-4-[(5-methyl-1,2-oxazol-3-yl)oxy]anilino]thieno[3,2-d]pyrimidin-6-yl]ethynyl]pyrrolidin-3-yl] morpholine-4-carboxylate
• CAS: 833479-08-6
• 化学式: C₂₇H₂₅ClN₆O₅S
• 分子量: 581.052
• InChiKey: SBYLTLVZZWSDEP-IEBWSBKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  40
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  152
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (3R,5S)-5-{[4-({3-chloro-4-[(5-methyl-3-isoxazolyl) oxy] phenyl} amino) thieno[3,2-d]pyrimidin-6-yl] ethynyl}-3-pyrrolidinyl 4-morpholinecarboxylate
  参考文献：
  名称：

  Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors

  摘要：

  Aniline 'headgroups' were synthesized and incorporated into an alkynyl thienopyrimidine series of EGFR and ErbB-2 inhibitors. Potent inhibition of enzyme activity and cellular proliferation was observed. In certain instances, protein binding was reduced and oral exposure was found to be somewhat improved relative to compounds containing the reference aniline. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.080

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005007083A2

  公开（公告）日：2005-01-27

  The present invention discloses thienopyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such thienopyrimidine derivatives are useful in the treatment of diseases associated with inappropriate ErbB family kinase activity.